AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26461847 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combined androgen blockade (CAB) for ≥ 6 months in patients with intermediate-risk prostate cancer with D90 < 180 Gy
Number of subjects: 431
Study 26461847 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant combined androgen blockade (CAB) and D90
Number of subjects: 431
Study 23354148 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program
Number of subjects: 61
Study 21539629 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercises
Number of subjects: 84
Study 21539629 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based exercises
Number of subjects: 84
Study 21539629 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 84
Study 18308095 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate (TURP) using the Gyrus PlasmaKinetic System (PK group)
Number of subjects: 120
Study 18308095 — intervention group
Group type: COMPARATOR
Intervention: Monopolar TURP (standard TURP group)
Number of subjects: 120
Study 18308095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PK and standard TURP groups
Number of subjects: 120
Study 16549129 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg morphine + 10 mg ropivacaine
Number of subjects: 30
Study 16549129 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg morphine + 10 mg ropivacaine
Number of subjects: 30
Study 14618032 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate control
Number of subjects: 0
Study 14618032 — intervention group
Group type: COMPARATOR
Intervention: Rhythm control
Number of subjects: 0
Study 11092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 150 microg/m2/d
Number of subjects: 69
Study 11092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 100 microg/m2/d
Number of subjects: 69
Study 11092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 50 microg/m2/d
Number of subjects: 69
Study 11092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim 25 microg/m2/d
Number of subjects: 69
Study 11092465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 11092465 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenograstim (all doses)
Number of subjects: 69
Study 7796592 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone-releasing vaginal ring (5 mg/24 h)
Number of subjects: 20
Study 7796592 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone-releasing vaginal ring (20 mg/24 h)
Number of subjects: 20
Study 7796592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both rings
Number of subjects: 20
Study 2370671 — intervention group
Group type: EXPERIMENTAL
Intervention: yohimbine
Number of subjects: 40
Study 2370671 — intervention group
Group type: COMPARATOR
Intervention: yohimbine and placebo
Number of subjects: 40
Study 2370671 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 2370671 — intervention group
Group type: COMPARATOR
Intervention: neither
Number of subjects: 40
Study 647693 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tamoxifen
Number of subjects: 4
Study 30060027 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir monotherapy
Number of subjects: 386
Study 29051501 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted one standard deviation higher isoleucine levels
Number of subjects: 17562
Study 29051501 — intervention group
Group type: COMPARATOR
Intervention: Leucine- and valine-raising allele
Number of subjects: 17562
Study 26386894 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Diaphragm Release Technique
Number of subjects: 20
Study 23644384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl plus placebo
Number of subjects: 48
Study 23644384 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl plus placebo
Number of subjects: 48
Study 23644384 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl plus dexmedetomidine
Number of subjects: 48
Study 23644384 — intervention group
Group type: COMPARATOR
Intervention: Fast tracking success rates
Number of subjects: 48
Study 21647901 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills training using the model
Number of subjects: 20
Study 21647901 — intervention group
Group type: COMPARATOR
Intervention: Didactic instruction
Number of subjects: 20
Study 20128318 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensodyne Extra Whitening
Number of subjects: 295
Study 20128318 — intervention group
Group type: COMPARATOR
Intervention: Crest Maximum Strength Sensitivity Protection Whitening plus Scope
Number of subjects: 295
Study 20128318 — intervention group
Group type: COMPARATOR
Intervention: Colgate Tartar Control Plus Whitening Mint
Number of subjects: 295
Study 16881943 — intervention group
Group type: EXPERIMENTAL
Intervention: < or = 6th grade literacy
Number of subjects: 235
Study 16881943 — intervention group
Group type: COMPARATOR
Intervention: > or = 9th grade literacy
Number of subjects: 235
Study 15266131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear mushrooms alone
Number of subjects: 34
Study 15266131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear mushrooms with additives
Number of subjects: 34
Study 15266131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11699405 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOP+ (cyclophosphamide, doxorubicin, vincristine, 6-mercaptopurine, and prednisone)
Number of subjects: 120
Study 11699405 — intervention group
Group type: COMPARATOR
Intervention: APO (doxorubicin, vincristine, 6-mercaptopurine, and prednisone)
Number of subjects: 120
Study 9329417 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicken-based diet
Number of subjects: 56
Study 9329417 — intervention group
Group type: COMPARATOR
Intervention: Vivonex (elemental diet)
Number of subjects: 56
Study 9329417 — intervention group
Group type: COMPARATOR
Intervention: Nursoy (soy diet)
Number of subjects: 56
Study 8281674 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 40 mg daily for 6 months
Number of subjects: 509
Study 8281674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 3353076 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone plus alizapride (800 mg i.v. total dose)
Number of subjects: 52
Study 3353076 — intervention group
Group type: COMPARATOR
Intervention: methylprednisolone (1 g i.v. total dose)
Number of subjects: 52
Study 31770574 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu injection (SFI) in combination with epinephrine
Number of subjects: 1233
Study 31770574 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with epinephrine alone
Number of subjects: 1233
Study 30477940 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 201
Study 28441266 — intervention group
Group type: EXPERIMENTAL
Intervention: IXIARO
Number of subjects: 1869
Study 28441266 — intervention group
Group type: COMPARATOR
Intervention: Prevnar
Number of subjects: 1869
Study 28441266 — intervention group
Group type: COMPARATOR
Intervention: HAVRIX
Number of subjects: 1869
Study 25980483 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (olanzapine 10-20 mg or risperidone 4-8 mg)
Number of subjects: 30
Study 25980483 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotics
Number of subjects: 30
Study 22718435 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily + Rifampin 300 mg daily
Number of subjects: 406
Study 22718435 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice daily + Placebo-Rifampin daily
Number of subjects: 406
Study 22718435 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 300 mg daily + Placebo-Doxycycline twice daily
Number of subjects: 406
Study 22718435 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Doxycycline twice daily + Placebo-Rifampin daily
Number of subjects: 406
Study 22718435 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline or Rifampin (alone or in combination)
Number of subjects: 406
Study 22718435 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (SMMSE, Quick mild cognitive impairment screen, Geriatric Depression Scale, Cornell Scale for Depression in Dementia, Lawton Scale, Dysfunctional Behavior Rating Instrument)
Number of subjects: 406
Study 21259251 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified parotidectomy technique
Number of subjects: 0
Study 21259251 — intervention group
Group type: COMPARATOR
Intervention: Conventional parotidectomy technique
Number of subjects: 0
Study 19399969 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized weaning
Number of subjects: 0
Study 19399969 — intervention group
Group type: COMPARATOR
Intervention: Non-protocolized practice
Number of subjects: 0
Study 16540931 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oxandrolone
Number of subjects: 262
Study 16540931 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oxandrolone
Number of subjects: 262
Study 16540931 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg oxandrolone
Number of subjects: 262
Study 16540931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 12640407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% levobupivacaine
Number of subjects: 60
Study 12640407 — intervention group
Group type: COMPARATOR
Intervention: 0.75% bupivacaine
Number of subjects: 60
Study 10730731 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac p.o. premedication
Number of subjects: 200
Study 10730731 — intervention group
Group type: COMPARATOR
Intervention: Placebo premedication
Number of subjects: 200
Study 9187292 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Card Sorting Test (MCST)
Number of subjects: 0
Study 1403175 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 3977547 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine hydrochloride
Number of subjects: 57
Study 3977547 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 57
Study 3977547 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine hydrochloride
Number of subjects: 57
Study 3977547 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa‐carbidopa (Sinemet)
Number of subjects: 57
Study 30959858 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone Med Adherence Stops Hypertension (SMASH)
Number of subjects: 54
Study 30959858 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard Care (ESC)
Number of subjects: 54
Study 30268627 — intervention group
Group type: EXPERIMENTAL
Intervention: High plane of milk (10 L/d)
Number of subjects: 26
Study 30268627 — intervention group
Group type: COMPARATOR
Intervention: Low plane of milk (5 L/d)
Number of subjects: 26
Study 25129282 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 20
Study 25129282 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 20
Study 25129282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACT and AIT pooled together
Number of subjects: 20
Study 25129282 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ACT and AIT
Number of subjects: 20
Study 21390413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Influenza Diagnostic Test (RIDT)
Number of subjects: 78
Study 21390413 — intervention group
Group type: EXPERIMENTAL
Intervention: ILI clinical data
Number of subjects: 78
Study 21390413 — intervention group
Group type: EXPERIMENTAL
Intervention: ILI clinical data and RIDT together
Number of subjects: 78
Study 21390413 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of RIDT
Number of subjects: 78
Study 19517600 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oils exposure; details on dosage and duration not specified.
Number of subjects: 0
Study 17404515 — intervention group
Group type: EXPERIMENTAL
Intervention: New DTPw-HBV vaccine
Number of subjects: 239
Study 17404515 — intervention group
Group type: COMPARATOR
Intervention: Licensed DTPw and HBV vaccines (given separately)
Number of subjects: 239
Study 17404515 — intervention group
Group type: COMPARATOR
Intervention: Licensed DTPw-HBV combination (Tritanrix-HepB)
Number of subjects: 239
Study 15205563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (2.5 mg daily for 3 months)
Number of subjects: 40
Study 15205563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15205563 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine vs Placebo
Number of subjects: 40
Study 15205563 — intervention group
Group type: COMPARATOR
Intervention: Bromocriptine and Placebo
Number of subjects: 40
Study 11701294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal and influenza immunization reminder letter (Group 3)
Number of subjects: 6600
Study 11701294 — intervention group
Group type: COMPARATOR
Intervention: Influenza immunization reminder letter only (Group 2)
Number of subjects: 6600
Study 11701294 — intervention group
Group type: COMPARATOR
Intervention: No letter (Group 1)
Number of subjects: 6600
Study 9032191 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized alpha1-protease inhibitor (200 mg)
Number of subjects: 29
Study 8485017 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (5 and 20 mg)
Number of subjects: 12
Study 8485017 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 and 100 mg)
Number of subjects: 12
Study 8485017 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (100 mg)
Number of subjects: 12
Study 3111784 — intervention group
Group type: EXPERIMENTAL
Intervention: NORPLANT implants
Number of subjects: 283
Study 3111784 — intervention group
Group type: COMPARATOR
Intervention: Two covered rods
Number of subjects: 283
Study 32609 — intervention group
Group type: EXPERIMENTAL
Intervention: Benorylate
Number of subjects: 85
Study 32609 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 85
Study 31856379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pecan nut group (PNG) - healthy diet plus 30 g day-1 of pecan nuts
Number of subjects: 204
Study 31856379 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - healthy diet according to nutritional guidelines
Number of subjects: 204
Study 31856379 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil group (OOG) - healthy diet plus 30 mL day-1 of extra-virgin olive oil
Number of subjects: 204
Study 31135272 — intervention group
Group type: EXPERIMENTAL
Intervention: Second person self-talk
Number of subjects: 16
Study 31135272 — intervention group
Group type: COMPARATOR
Intervention: First person self-talk
Number of subjects: 16
Study 28948836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics consultation simulation
Number of subjects: 0
Study 28948836 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic format
Number of subjects: 0
Study 26175260 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice
Number of subjects: 1582
Study 26175260 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 1582
Study 22885142 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic pulses delivered in an anterioposterior direction (posteriorly directed)
Number of subjects: 8
Study 22885142 — intervention group
Group type: COMPARATOR
Intervention: Biphasic pulses directed posteroanterior (anteriorly)
Number of subjects: 8
Study 22885142 — intervention group
Group type: COMPARATOR
Intervention: Monophasic pulses from either direction
Number of subjects: 8
Study 22885142 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz study with posteriorly directed biphasic pulses
Number of subjects: 8
Study 20561179 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM 900 exposure
Number of subjects: 30
Study 20561179 — intervention group
Group type: EXPERIMENTAL
Intervention: WCDMA exposure
Number of subjects: 30
Study 20561179 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 30
Study 19732949 — intervention group
Group type: EXPERIMENTAL
Intervention: Full screening of windows, doors, and closing eaves
Number of subjects: 755
Study 19732949 — intervention group
Group type: EXPERIMENTAL
Intervention: Screened ceilings
Number of subjects: 755
Study 19732949 — intervention group
Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 755
Study 24683680 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified rice substitution for habitual rice consumption
Number of subjects: 300
Study 24683680 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet without biofortified rice
Number of subjects: 300
Study 15279528 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure only (EO)
Number of subjects: 72
Study 15279528 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with phobic safety-behavior availability (SBA)
Number of subjects: 72
Study 15279528 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure with safety-behavior utilization (SBU)
Number of subjects: 72
Study 15279528 — intervention group
Group type: COMPARATOR
Intervention: Credible placebo treatment (PL)
Number of subjects: 72
Study 15279528 — intervention group
Group type: COMPARATOR
Intervention: Wait list (WL)
Number of subjects: 72
Study 11515715 — intervention group
Group type: EXPERIMENTAL
Intervention: Crataegus extract WS 1442 (3 x 1 capsule)
Number of subjects: 40
Study 11515715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9571266 — intervention group
Group type: EXPERIMENTAL
Intervention: RGP contact lenses
Number of subjects: 13
Study 9571266 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible gas permeable lenses
Number of subjects: 13
Study 9571266 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 13
Study 9571266 — intervention group
Group type: COMPARATOR
Intervention: Spectacle correction
Number of subjects: 13
Study 7938794 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural drainage combined with forced expiratory technique (PD+FET)
Number of subjects: 14
Study 7938794 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure breathing combined with forced expiratory technique (PEP+FET)
Number of subjects: 14
Study 2967477 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg
Number of subjects: 6
Study 2967477 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone methylsulfobenzoate 30 mg
Number of subjects: 6
Study 31841279 — intervention group
Group type: EXPERIMENTAL
Intervention: Central blood pressure (BP) measurement
Number of subjects: 0
Study 31841279 — intervention group
Group type: EXPERIMENTAL
Intervention: Central BP strategy for confirming a diagnosis of hypertension
Number of subjects: 0
Study 31841279 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance of hypertension management with central BP
Number of subjects: 0
Study 31841279 — intervention group
Group type: COMPARATOR
Intervention: Central BP-guided therapeutic strategies
Number of subjects: 0
Study 29602646 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (cohort A)
Number of subjects: 79
Study 29602646 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (cohort B)
Number of subjects: 79
Study 29602646 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (cohort C)
Number of subjects: 79
Study 28293063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to standard chemotherapy
Number of subjects: 207
Study 28293063 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 207
Study 28293063 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 207
Study 26887366 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline quadruple therapy
Number of subjects: 135
Study 26887366 — intervention group
Group type: COMPARATOR
Intervention: Tailored therapy
Number of subjects: 135
Study 26887366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study 24285457 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% urea lotion
Number of subjects: 41
Study 24285457 — intervention group
Group type: COMPARATOR
Intervention: Liquid petrolatum
Number of subjects: 41
Study 21569813 — intervention group
Group type: EXPERIMENTAL
Intervention: Solicited self-reporting
Number of subjects: 2675
Study 21569813 — intervention group
Group type: COMPARATOR
Intervention: Unsolicited self-reporting
Number of subjects: 2675
Study 18468269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-needling
Number of subjects: 45
Study 18468269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% lidocaine
Number of subjects: 45
Study 18468269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% lidocaine associated with corticoid
Number of subjects: 45
Study 17077202 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 0
Study 17077202 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 17077202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15555719 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/day)
Number of subjects: 300
Study 15555719 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20 mg/day)
Number of subjects: 300
Study 11371420 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction
Number of subjects: 79
Study 9226144 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint analysis for assessing preferences
Number of subjects: 0
Study 8217301 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy plus operation
Number of subjects: 260
Study 8217301 — intervention group
Group type: COMPARATOR
Intervention: Operation alone
Number of subjects: 260
Study 2967186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg day‐1
Number of subjects: 315
Study 2967186 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg day‐1
Number of subjects: 315
Study 2967186 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg day‐1
Number of subjects: 315
Study 29682796 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ‐39758979 300 mg once daily for 12 weeks
Number of subjects: 115
Study 29682796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115